EAM
OVID icon

Eventide Asset Management’s Ovid Therapeutics OVID Stock Holding History

Eventide Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22M Buy
9,916,911
+5,631,911
+131% +$10.1M 0.36% 99
2025
Q4 		$6.98M Buy
+4,285,000
New +$6.6M 0.11% 160

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Eventide Asset Management's OVID Position: Q1 2026 in Review

Eventide Asset Management increased its Ovid Therapeutics (OVID) stake by 131% in Q1 2026, buying an estimated $10.1M and bringing the position to 9,916,911 shares worth $22M. The position accounts for 0.36% of the portfolio, ranked #99.

Eventide Asset Management first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Eventide Asset Management held 9,916,911 shares of Ovid Therapeutics worth $22M as of Q1 2026.
  • Eventide Asset Management bought 5,631,911 Ovid Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Ovid Therapeutics made up 0.36% of Eventide Asset Management's portfolio in Q1 2026, its #99 holding.
  • Eventide Asset Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.